CN113855712A - 可促进排便的组合物及其用途 - Google Patents
可促进排便的组合物及其用途 Download PDFInfo
- Publication number
- CN113855712A CN113855712A CN202110349295.3A CN202110349295A CN113855712A CN 113855712 A CN113855712 A CN 113855712A CN 202110349295 A CN202110349295 A CN 202110349295A CN 113855712 A CN113855712 A CN 113855712A
- Authority
- CN
- China
- Prior art keywords
- strain
- composition
- lactobacillus
- lactic acid
- acid bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 230000013872 defecation Effects 0.000 title claims abstract description 26
- 230000001737 promoting effect Effects 0.000 title claims abstract description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 88
- 239000000843 powder Substances 0.000 claims abstract description 53
- 241000894006 Bacteria Species 0.000 claims abstract description 50
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 44
- 239000004310 lactic acid Substances 0.000 claims abstract description 44
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 239000003085 diluting agent Substances 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 15
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 15
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 15
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 14
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 11
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 11
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims description 44
- 230000004151 fermentation Effects 0.000 claims description 44
- 239000002775 capsule Substances 0.000 claims description 28
- 241000186660 Lactobacillus Species 0.000 claims description 26
- 229940039696 lactobacillus Drugs 0.000 claims description 26
- 206010010774 Constipation Diseases 0.000 claims description 15
- 235000013305 food Nutrition 0.000 claims description 13
- 210000003608 fece Anatomy 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 235000015140 cultured milk Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 235000020124 milk-based beverage Nutrition 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 2
- 230000008021 deposition Effects 0.000 claims 4
- 235000013336 milk Nutrition 0.000 abstract description 8
- 239000008267 milk Substances 0.000 abstract description 8
- 210000004080 milk Anatomy 0.000 abstract description 8
- 235000010469 Glycine max Nutrition 0.000 abstract description 3
- 244000046052 Phaseolus vulgaris Species 0.000 abstract description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 abstract description 3
- 239000005862 Whey Substances 0.000 abstract description 3
- 102000007544 Whey Proteins Human genes 0.000 abstract description 3
- 108010046377 Whey Proteins Proteins 0.000 abstract description 3
- 239000005018 casein Substances 0.000 abstract description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract description 3
- 235000021240 caseins Nutrition 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000005913 Maltodextrin Substances 0.000 description 9
- 229920002774 Maltodextrin Polymers 0.000 description 9
- 230000003203 everyday effect Effects 0.000 description 9
- 229940035034 maltodextrin Drugs 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000008144 emollient laxative Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960002983 loperamide hydrochloride Drugs 0.000 description 1
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000009931 pascalization Methods 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/06—Treating cheese curd after whey separation; Products obtained thereby
- A23C19/061—Addition of, or treatment with, microorganisms
- A23C19/062—Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/08—Oxidation; Fermentation
- A23F3/10—Fermentation with addition of microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/166—Addition of, or treatment with, enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/02—Treating green coffee; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
- A23F5/24—Extraction of coffee; Coffee extracts; Making instant coffee
- A23F5/246—Addition of, or treatment with, enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种可促进排便的组合物,其包括:乳酸菌发酵粉末,包含乳酸菌发酵物,乳酸菌发酵物为将至少乳酸菌菌株培养于包含牛奶、奶粉、酪蛋白、大豆、豆类制品、或乳清的培养基而取得的,乳酸菌菌株包含唾液乳酸杆菌AP‑32菌株、植物乳酸杆菌LPL28菌株、嗜酸乳酸杆菌TYCA06菌株、长双歧杆菌婴儿亚种BLI‑02菌株或其组合;以及生理上可接受的赋形剂、稀释剂、或载体。
Description
技术领域
本发明关于一种组合物,且特别涉及一种可促进排便的组合物及其用途。
背景技术
便秘意指粪便干硬,排便困难,导致排便减少的一种症状,通常为大肠蠕动功能不足使粪便在大肠的通过或直肠的排出延迟。若粪便停留在直肠的时间过久,分解的食物在大肠内受细菌长时间发酵,容易产生毒素或有害气体等;若不能按时排出,则人体将再次吸收这些有害物质,进一步进入血液中,对人体造成危害,并导致许多慢性或代谢疾病。
大多数治疗便秘的非处方用药,如:泻药或粪便软化剂,但这些常见药剂服用后会产生副作用,长时间服用会有依赖性,且对于身体会有极大伤害。
根据The American Journal of Clinical Nutrition于2014年报导的研究论文,显示乳酸菌可帮助维持肠道平衡,改善食物于肠道的运输时间,排便频率与粪便稠度,长时间服用可改善便秘情形。然而,乳酸菌定义为一种对人体有益的活菌,若乳酸菌黏附或定植在肠道的数量不足时,则维持肠道平衡及改善便秘情形将会大打折扣。
综上所述,开发一种安全且可长期服用并可促进排便效果的补充品有其迫切性。然而,乳酸菌发酵产物相对于多数治疗便秘的非处方用药为安全不伤害人体的,且可快速为人体吸收,故寻找具有促进排便效果且可制作成改善便秘的组合物的乳酸菌发酵产物为本发明所属技术领域目前亟需努力的目标之一。
发明内容
本发明之目的在于提出一种可促进排便的乳酸菌发酵粉末,其可促进排便次数,并以食品组合物或医药组合物等不同形式存在来改善便秘。
于是,本发明提出一种可促进排便的组合物,其包括:乳酸菌发酵粉末,包含乳酸菌发酵物,乳酸菌发酵物为将至少乳酸菌菌株培养于包含牛奶、奶粉、酪蛋白、大豆、豆类制品、或乳清的培养基而取得的,乳酸菌菌株包含唾液乳酸杆菌(Lactobacillus salivariussubsp.salicinius)AP-32菌株、植物乳酸杆菌(Lactobacillus plantarum)LPL28菌株、嗜酸乳酸杆菌(Lactobacillus acidophilus)TYCA06菌株、长双歧杆菌婴儿亚种(Bifidobacterium longum subsp.infantis)BLI-02菌株或其组合;以及生理上可接受的赋形剂、稀释剂、或载体;其中唾液乳酸杆菌AP-32菌株寄存于中国典型培养物保藏中心,寄存编号为CCTCC M2011127,植物乳酸杆菌(Lactobacillus plantarum)LPL28菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 17954,嗜酸乳酸杆菌(Lactobacillusacidophilus)TYCA06菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC15210,长双歧杆菌婴儿亚种(Bifidobacterium longum subsp.infantis)BLI-02菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 15212。
较佳地,乳酸菌菌株包含唾液乳酸杆菌(Lactobacillus salivariussubsp.salicinius)AP-32菌株、植物乳酸杆菌(Lactobacillus plantarum)LPL28菌株、嗜酸乳酸杆菌(Lactobacillus acidophilus)TYCA06菌株、以及长双歧杆菌婴儿亚种(Bifidobacterium longum subsp.infantis)BLI-02菌株。
较佳地,组合物为医药组合物或食品组合物,但不以此为限。
较佳地,在组合物为医药组合物时,生理上可接受的赋形剂、稀释剂、或载体为药用上可接受的赋形剂、稀释剂、或载体,但不以此为限。
较佳地,医药组合物呈锭剂、胶囊、粉剂、乳膏、喷雾剂、凝胶、溶液剂、散剂、或霜剂形式,但不以此为限。
较佳地,于组合物为食品组合物时,生理上可接受的赋形剂、稀释剂、或载体为食用上可接受的赋形剂、稀释剂、或载体,但不以此为限。
较佳地,食品组合物为发酵乳、优格、奶酪、乳制饮品乳粉、茶、咖啡、机能性饮品、或其组合,但不以此为限。
较佳地,以组合物总重量为基础,乳酸菌发酵物占2至40重量%。
较佳地,乳酸菌发酵物为培养基的发酵上层液、培养基包含去活性菌株的发酵上层液、培养基去除菌体的发酵上层液、或其干燥粉末,但不以此为限。
较佳地,组合物更包括:益生元。
有鉴于上述组合物在人体或动物体内可促进排便的效果,本发明尚提出上述组合物的用途,其为用于制备改善便秘的组合物。
较佳地,便秘症状包含:粪便干硬、粪便量少、排便费力、排便不干净、或排便次数减少。
附图说明
图1为长条统计图,用于呈现不同组别的受试者的排便次数统计。
图2为长条统计图,用于呈现受试者服用不同种类或不同剂量的胶囊后的肠胃健康体感舒适感。
图3为长条统计图,用于呈现不同组别的受试者的菌丛改变程度。
具体实施方式
为让本发明上述及/或其他目的、功效、特征更明显易懂,下文特举较佳实施方式,作详细说明如下:
本发明所述的乳酸菌菌株的冷冻干燥培养物寄存于中国典型培养物保藏中心,地址为中国、武汉、武汉大学,或寄存于中国普通微生物菌种保藏管理中心,地址为北京市朝阳区北辰西路1号院3号。寄存详细资料如下述表1所示:
表1、乳酸菌菌株的寄存资料
本发明人发现如上述表1所列的菌株的发酵物具有增加排便次数的功效。因此,利用此发酵物制作成粉末制作成组合物以改善便秘。
本发明之一实施方式提出一种可促进排便的组合物,此组合物包括:乳酸菌发酵粉末,包含乳酸菌发酵物,乳酸菌发酵物为将至少乳酸菌菌株培养于包含牛奶、奶粉、酪蛋白、大豆、豆类制品、或乳清的培养基而取得的,乳酸菌菌株包含寄存于中国典型培养物保藏中心,寄存编号为CCTCC M2011127的唾液乳酸杆菌(Lactobacillus salivariussubsp.salicinius)AP-32菌株、寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 17954的植物乳酸杆菌(Lactobacillus plantarum)LPL28菌株、寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 15210的嗜酸乳酸杆菌(Lactobacillusacidophilus)TYCA06菌株、寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC15212的长双歧杆菌婴儿亚种(Bifidobacterium longum subsp.infantis)BLI-02菌株、或其组合;以及生理上可接受的赋形剂、稀释剂、或载体。在一较佳例中,以组合物总重量为基础,乳酸菌发酵物占2至40重量%。在另一较佳例中,乳酸菌发酵物为培养基的发酵上层液、培养基包含去活性菌株的发酵上层液、培养基去除菌体的发酵上层液、或其干燥粉末。在又一较佳例中,乳酸菌菌株至少包含上述四种菌株。
此外,为符合实际使用需求,本实施方式的组合物可呈医药组合物或食品组合物形式。而在呈医药组合物形式的条件下,生理上可接受的赋形剂、稀释剂、或载体为药用上可接受的赋形剂、稀释剂、或载体,而医药组合物呈锭剂、胶囊、粉剂、乳膏、喷雾剂、凝胶、溶液剂、散剂、或霜剂形式;在呈食品组合物形式的条件下,生理上可接受的赋形剂、稀释剂、或载体为食用上可接受的赋形剂、稀释剂、或载体,而食品组合物为发酵乳、优格、奶酪、乳制饮品乳粉、茶、咖啡、或机能性饮品。另外,为协助肠胃道内的有益菌生长,本实施方式的组合物可进一步地包含益生元。而且,透过益生元的添加亦可提升肠胃道机能而增加本实施方式的组合物的排便效果。
基于上述实施方式的组合物的机能,本发明的另一实施方式提出一种上述组合物的用途,其为用于制备改善便秘的组合物,而便秘症状至少包含粪便干硬、粪便量少、排便费力、排便不干净、或排便次数减少。
<实施例1:乳酸菌菌株的形态学与一般性质>
采用16s rRNA序列分析法与API细菌鉴定系统来确认菌株于分类学上的特征,本实施例的菌株在形态学及一般性质的特征如表2所示:
表2、乳酸菌菌株的形态学与一般性质特征
<实施例2:制作乳酸菌发酵粉末>
本实施例的乳酸菌发酵粉末的制作为先以包含牛奶、奶粉、酪蛋白、大豆、豆类制品、或乳清的培养基培养上述经分离之唾液乳酸杆菌AP-32菌株、植物乳酸杆菌LPL28菌株、嗜酸乳酸杆菌TYCA06菌株、及长双歧杆菌婴儿亚种BLI-02菌株的组合以进行发酵。接着,对培养基离心取发酵液后,以热灭菌方式去除发酵液的菌株活性、去除发酵液的菌体、或使其干燥形成干燥粉末。此外,干燥粉末可作为本实施例的乳酸菌发酵粉末;而去菌株活性的发酵液或去除菌体的发酵液再经处理以形成本实施例的乳酸菌发酵粉末。
<实施例3:乳酸菌发酵粉末的排便测试>
本实施例测试上述实施例的乳酸菌发酵粉末在人体内的促进排便效果。首先,取200mg乳酸菌发酵粉末与麦芽糊精混合成胶囊,使胶囊内含物达500mg;另取500mg麦芽糊精制作成胶囊作为对照组。接着,将45位受试者分成三组,每组15位,并记录每位受试者受试前的每周排便次数。之后,其中一组每日服用仅麦芽糊精的对照组胶囊,另组每日服用一颗含200mg乳酸菌发酵粉末的胶囊,另组每日服用三颗含200mg乳酸菌发酵粉末的胶囊,为期一个月,并记录每位受试者服用最后一周的排便次数。
如图1所示,服用对照组胶囊组别的受试者的排便次数并无增加,表示麦芽糊精无法促进排便;每日服用200mg乳酸菌发酵粉末组别的受试者的排便次数些微增加但不显著;每日服用600mg乳酸菌发酵粉末组别的受试者的排便次数明显增加。综上,本实施例证实乳酸菌发酵粉末可提升排便频率。
<实施例4:乳酸菌发酵粉末的肠胃健康体感测试>
本实施例测试上述实施例的乳酸菌发酵粉末在人体内的肠胃健康体感舒适感。首先,取200mg乳酸菌发酵粉末与麦芽糊精混合成胶囊,使胶囊内含物达500mg;另取500mg麦芽糊精制作成胶囊作为对照组。接着,将15位受试者分成三组,每组5位。之后,每组依随机顺序服用对照组胶囊、一颗含200mg乳酸菌发酵粉末的胶囊、及三颗含200mg乳酸菌发酵粉末的胶囊各一段期间,服用前一类胶囊迄至服用后一种类胶囊起的间隔为一周,并于服用每一种类胶囊期间纪录便秘改善、胀气改善,腹泻改善、上腹痛改善、及下腹痛改善等体感评分。
如图2所示,服用对照组胶囊组别后,受试者未感觉到肠胃舒适感提升;每日服用200mg乳酸菌发酵粉末后,受试者稍感觉到肠胃舒适感提升但不显著;每日服用600mg乳酸菌发酵粉末后,受试者明显感觉到肠胃舒适感提升。综上,本实施例证实乳酸菌发酵粉末可提升肠胃健康体感舒适感。
<实施例5:乳酸菌发酵粉末的肠胃道菌相测试>
本实施例测试上述实施例的乳酸菌发酵粉末在人体肠胃道菌相的影响。首先,取200mg乳酸菌发酵粉末与麦芽糊精混合成胶囊,使胶囊内含物达500mg;另取500mg麦芽糊精制作成胶囊作为对照组。接着,将45位受试者分成三组,每组15位,并取每位受试者受试前的粪便样本。之后,其中一组每日服用仅麦芽糊精的对照组胶囊,另组每日服用一颗含200mg乳酸菌发酵粉末的胶囊,另组每日服用三颗含200mg乳酸菌发酵粉末的胶囊,为期一个月,并取每位受试者受试后的粪便样本。最后,利用次世代定序方法(next generationsequencing,NGS)检测粪便样本的菌相。
Bifidobacterium、Akkermansia、Lactococcus、以及Lactobacillus归类为益生菌,而Enterococcus和Streptococcus则归类为致病菌。如图3所示,服用对照组胶囊组别的受试者的致病菌丛有些微增加的趋势,而益生菌丛有些微减少的趋势;每日服用200mg乳酸菌发酵粉末组别的受试者的致病菌丛与益生菌丛均有些微增加的趋势;每日服用600mg乳酸菌发酵粉末组别的受试者的致病菌丛有明显减少的趋势,而益生菌丛有明显增加的趋势。
<实施例6:乳酸菌发酵粉末的粪便含水量测试>
本实施例测试上述实施例的乳酸菌发酵粉末于便秘小鼠粪便含水量的影响。首先,利用喂食或注射七至八周大的Balb/c老鼠止泻药洛哌丁胺(loperamidehydrochloride)来建立便秘小鼠的动物模型。接着,将小鼠分组成:对照组、唾液乳酸杆菌AP-32菌株发酵物组、植物乳酸杆菌LPL28菌株发酵物组、嗜酸乳酸杆菌TYCA06菌株发酵物组、长双歧杆菌婴儿亚种BLI-02菌株发酵物组、四联菌株发酵物组、及四联菌株活菌组,其中,「四联菌株」用语意指上述唾液乳酸杆菌AP-32菌株、植物乳酸杆菌LPL28菌株、嗜酸乳酸杆菌TYCA06菌株、及长双歧杆菌婴儿亚种BLI-02菌株的组合。然后,进行喂灌,灌喂时以0.25mL生理食盐水作为溶剂,且每日灌喂2次,共灌喂8天;其中「对照组」每次仅灌喂生理食盐水;「唾液乳酸杆菌AP-32菌株发酵物组」、「植物乳酸杆菌LPL28菌株发酵物组」、「嗜酸乳酸杆菌TYCA06菌株发酵物组」、及「长双歧杆菌婴儿亚种BLI-02菌株发酵物组」每次灌喂600mg对应的单种乳酸菌菌株发酵物;「四联菌株发酵物组」每次灌喂600mg四联菌株发酵物(单种乳酸菌菌株发酵物150mg);「四联菌株活菌组」每次灌喂2x1010cfu四联菌株活菌(单种乳酸菌菌株活菌5x109cfu)。之后,收集小鼠粪便并计算含水量,粪便含水量公式如下:
粪便含水量(%)=(粪便湿重-粪便干重)/粪便湿重×100%
粪便含水量分析结果如表3所示:
表3、粪便含水量分析结果
由上表可知,四联菌株发酵物组增加的粪便含水量(0.3%)远高于唾液乳酸杆菌AP-32菌株发酵物组、植物乳酸杆菌LPL28菌株发酵物组、嗜酸乳酸杆菌TYCA06菌株发酵物组、及长双歧杆菌婴儿亚种BLI-02菌株发酵物组增加之粪便含水量的平均值(0.2%)。这表示四联菌株发酵物组对粪便含水量的增加产生协同效应。综上,本实施例证实实施例1取得的乳酸菌发酵粉末可不可预料地提升粪便含水量。
须注意的是,乳酸菌发酵粉末为乳酸菌代谢产物的混合物,对人体健康的功能归咎于组成养分的特异性,而非仅乳酸菌活菌本身,此种对人体健康有特殊功效的代谢产物泛称为“后生元(postbiotics)”(请参照Trends in Food Science&Technology.2018-05,75:105-114)。另外,人体对后生元的反应性取决于菌种、完善的培养、加工过程、与完整的临床报告。举例而言,根据2019年发表于International Journal of Molecular SciencesVol.20No.19的论文,其数据指出目前已知的后生元加工方式,包括:热封存处理、物理性处理、高静水压处理、冷冻干燥、或超音波震荡等,绝非随意加工处理即能达到促进健康的功效。
惟以上所述者,仅为本发明的较佳实施例,但不能以此限定本发明的保护范围;故,凡依本发明申请专利保护范围及发明说明书内容所作的简单的等效改变与修饰,皆仍落入本发明专利保护范围内。
Claims (10)
1.一种可促进排便的组合物,其特征在于,包括:乳酸菌发酵粉末,包含乳酸菌发酵物,该乳酸菌发酵物为将至少乳酸菌菌株培养在包含牛奶、奶粉、酪蛋白、大豆、豆类制品、或乳清的培养基而取得的,所述乳酸菌菌株包含唾液乳酸杆菌AP-32菌株、植物乳酸杆菌LPL28菌株、嗜酸乳酸杆菌TYCA06菌株、长双歧杆菌婴儿亚种BLI-02菌株、或其组合;其中该唾液乳酸杆菌AP-32菌株寄存于中国典型培养物保藏中心,寄存编号为CCTCC M2011127,该植物乳酸杆菌LPL28菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 17954,该嗜酸乳酸杆菌TYCA06菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC15210,该长双歧杆菌婴儿亚种BLI-02菌株寄存于中国普通微生物菌种保藏管理中心,寄存编号为CGMCC 15212;以及
生理上可接受的赋形剂、稀释剂、或载体。
2.如权利要求1所述的组合物,其特征在于:该乳酸菌菌株包含唾液乳酸杆菌AP-32菌株、植物乳酸杆菌LPL28菌株、嗜酸乳酸杆菌TYCA06菌株、以及长双歧杆菌婴儿亚种BLI-02菌株。
3.如权利要求1所述的组合物,其特征在于:所述组合物为医药组合物或食品组合物。
4.如权利要求3所述的组合物,其特征在于:该组合物为食品组合物时,该生理上可接受的赋形剂、稀释剂、或载体为食用上可接受的赋形剂、稀释剂、或载体,而该食品组合物为发酵乳、优格、奶酪、乳制饮品乳粉、茶、咖啡、机能性饮品、或其组合。
5.如权利要求3所述的组合物,其特征在于:该组合物为医药组合物时,该生理上可接受的赋形剂、稀释剂、或载体为药用上可接受的赋形剂、稀释剂、或载体,而该医药组合物呈锭剂、胶囊、粉剂、乳膏、喷雾剂、凝胶、溶液剂、散剂、或霜剂形式。
6.如权利要求1所述的组合物,其特征在于:该组合物总重量为基础,该乳酸菌发酵物占2至40重量%。
7.如权利要求1所述的组合物,其特征在于:该乳酸菌发酵物为培养基的发酵上层液、培养基包含去活性菌株的发酵上层液、培养基去除菌体的发酵上层液、或其干燥粉末。
8.如权利要求1所述的组合物,其特征在于:还包括益生元。
9.一种如权利要求1至8任一权利要求所述的组合物的用途,其特征在于:用于制备改善便秘的组合物。
10.如权利要求9所述的用途,其特征在于,该便秘症状包含:粪便干硬、粪便量少、排便费力、排便不干净、或排便次数减少。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22778484.0A EP4316270A1 (en) | 2020-06-29 | 2022-03-08 | Composition capable of facilitating defecation and use thereof |
PCT/CN2022/079636 WO2022206300A1 (zh) | 2020-06-29 | 2022-03-08 | 可促进排便的组合物及其用途 |
JP2023546382A JP2023544655A (ja) | 2020-06-29 | 2022-03-08 | 排便を促進する組成物及びその用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW109121775 | 2020-06-29 | ||
TW109121775A TWI739495B (zh) | 2020-06-29 | 2020-06-29 | 可促進排便的組合物及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113855712A true CN113855712A (zh) | 2021-12-31 |
CN113855712B CN113855712B (zh) | 2022-10-28 |
Family
ID=78778201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110349295.3A Active CN113855712B (zh) | 2020-06-29 | 2021-03-31 | 可促进排便的组合物及其用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11717546B2 (zh) |
EP (1) | EP4316270A1 (zh) |
JP (1) | JP2023544655A (zh) |
CN (1) | CN113855712B (zh) |
TW (1) | TWI739495B (zh) |
WO (1) | WO2022206300A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022180587A1 (zh) * | 2021-02-26 | 2022-09-01 | 丰华生物科技股份有限公司 | 提升口腔免疫球蛋白a含量及抑制病原菌的组合物及用途 |
WO2022206300A1 (zh) * | 2020-06-29 | 2022-10-06 | 丰华生物科技股份有限公司 | 可促进排便的组合物及其用途 |
CN115581302A (zh) * | 2022-10-27 | 2023-01-10 | 海普诺凯营养品有限公司 | 一种减脂组合物、减脂产品及其用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI800740B (zh) * | 2020-06-30 | 2023-05-01 | 豐華生物科技股份有限公司 | 促進排便的組成物及其應用 |
CN115141860A (zh) * | 2021-03-31 | 2022-10-04 | 锦乔生物科技有限公司 | 用于生产γ-胺基丁酸的方法及其所制得的发酵培养物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060251633A1 (en) * | 2002-02-28 | 2006-11-09 | Salvadori Bruna B | Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations |
CN103764154A (zh) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | 包含片球菌属的药物组合物和减轻胃肠综合征的症状的方法 |
WO2014119605A1 (ja) * | 2013-01-29 | 2014-08-07 | 日東薬品工業株式会社 | ビフィズス菌を含有する安定な組成物 |
CN108740251A (zh) * | 2018-06-15 | 2018-11-06 | 广东燕岭生命科技股份有限公司 | 一种改善便秘的益生菌凝胶糖果及其制备方法 |
CN108991327A (zh) * | 2018-07-24 | 2018-12-14 | 北京奥维森基因健康科技有限公司 | 一种益生菌固体饮料及其制备方法 |
WO2020008149A1 (fr) * | 2018-07-04 | 2020-01-09 | Institut National De La Recherche Agronomique | Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100166721A1 (en) * | 2006-06-09 | 2010-07-01 | Fabiola Masri | Probotic compositions and uses thereof |
CN109432136A (zh) * | 2018-10-31 | 2019-03-08 | 张志澎 | 一种益生菌组合制剂及其制备方法和应用 |
TWI739495B (zh) * | 2020-06-29 | 2021-09-11 | 豐華生物科技股份有限公司 | 可促進排便的組合物及其用途 |
CN111743159B (zh) * | 2020-07-17 | 2022-09-27 | 江南大学 | 复合微生物制剂及缓解抑郁和便秘的应用 |
-
2020
- 2020-06-29 TW TW109121775A patent/TWI739495B/zh active
-
2021
- 2021-03-31 CN CN202110349295.3A patent/CN113855712B/zh active Active
- 2021-05-03 US US17/246,977 patent/US11717546B2/en active Active
-
2022
- 2022-03-08 EP EP22778484.0A patent/EP4316270A1/en active Pending
- 2022-03-08 WO PCT/CN2022/079636 patent/WO2022206300A1/zh active Application Filing
- 2022-03-08 JP JP2023546382A patent/JP2023544655A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060251633A1 (en) * | 2002-02-28 | 2006-11-09 | Salvadori Bruna B | Dietetic and/or pharmaceutical compositions for human and/or animal use based on probiotic microbial preparations |
CN103764154A (zh) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | 包含片球菌属的药物组合物和减轻胃肠综合征的症状的方法 |
WO2014119605A1 (ja) * | 2013-01-29 | 2014-08-07 | 日東薬品工業株式会社 | ビフィズス菌を含有する安定な組成物 |
CN108740251A (zh) * | 2018-06-15 | 2018-11-06 | 广东燕岭生命科技股份有限公司 | 一种改善便秘的益生菌凝胶糖果及其制备方法 |
WO2020008149A1 (fr) * | 2018-07-04 | 2020-01-09 | Institut National De La Recherche Agronomique | Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin |
CN108991327A (zh) * | 2018-07-24 | 2018-12-14 | 北京奥维森基因健康科技有限公司 | 一种益生菌固体饮料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
JOAQUIN ESCRIBANO 等: ""Bifidobacterium longum subsp infantis CECT7210-supplemented formula reduces diarrhea in healthy infants: a randomized controlled trial"", 《PEDIATR RES.》 * |
JUE-RONG FENG等: ""Efficacy and safety of probiotic-supplemented triple therapy for eradication of Helicobacter pylori in children: a systematic review and network meta-analysis"", 《EUR J CLIN PHARMACOL》 * |
应聪萍: ""缓解便秘的双歧杆菌筛选及益生特性解析"", 《中国优秀博硕士学位论文全文数据库(硕士) 工程科技I辑》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022206300A1 (zh) * | 2020-06-29 | 2022-10-06 | 丰华生物科技股份有限公司 | 可促进排便的组合物及其用途 |
WO2022180587A1 (zh) * | 2021-02-26 | 2022-09-01 | 丰华生物科技股份有限公司 | 提升口腔免疫球蛋白a含量及抑制病原菌的组合物及用途 |
CN115581302A (zh) * | 2022-10-27 | 2023-01-10 | 海普诺凯营养品有限公司 | 一种减脂组合物、减脂产品及其用途 |
CN115581302B (zh) * | 2022-10-27 | 2023-12-22 | 海普诺凯营养品有限公司 | 一种减脂组合物、减脂产品及其用途 |
Also Published As
Publication number | Publication date |
---|---|
JP2023544655A (ja) | 2023-10-24 |
TWI739495B (zh) | 2021-09-11 |
WO2022206300A1 (zh) | 2022-10-06 |
EP4316270A1 (en) | 2024-02-07 |
US20210401908A1 (en) | 2021-12-30 |
CN113855712B (zh) | 2022-10-28 |
TW202200029A (zh) | 2022-01-01 |
US11717546B2 (en) | 2023-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113855712B (zh) | 可促进排便的组合物及其用途 | |
US7901925B2 (en) | Lactobacillus delbrueckii ssp. bulgaricus strain and compositions | |
TWI594758B (zh) | 包含雙歧桿菌的組合物、其製備方法及其用途 | |
CN104413334A (zh) | 可食用组合物及其制备方法和用途 | |
JP2009511469A (ja) | 脂肪代謝及び肥満に影響を及ぼすプロバイオティクス | |
CN105985918B (zh) | 抗肥胖的乳酸菌菌株及其在食品组成物以及医药组成物中的应用 | |
CN110205270B (zh) | 一种缓解养殖动物便秘的副干酪乳杆菌l9的应用 | |
CN104415060A (zh) | 可食用组合物及其制备方法和用途 | |
CN113583923B (zh) | 一种益生菌组合物及其在制备共病便秘抑郁症药物中的应用 | |
CN106036911A (zh) | 一种调节血糖水平的益生菌膳食组合物及功能食品 | |
JP2021524751A (ja) | 組成物及びその使用 | |
CN115089619A (zh) | 植物乳杆菌zdy2013在具有缓解非酒精性脂肪肝功能的制剂中的应用 | |
JP3017493B1 (ja) | 自己免疫疾患予防組成物 | |
JP5681533B2 (ja) | 消化管痛の予防又は軽減剤 | |
CN109207389B (zh) | 一种消栓降脂益生复合菌中药口服液及其制备方法 | |
CN111035658A (zh) | 戊糖片球菌的用途 | |
CN111035661A (zh) | 植物乳杆菌的用途 | |
CN112190600A (zh) | 一株植物乳杆菌在制备缓解机体慢性炎症的组合物中的应用 | |
WO2008002484A2 (en) | Novel lactobacillus bulgaricus strain and compositions | |
WO2019227414A1 (zh) | 一种组合物及其应用 | |
CN115838675A (zh) | 一种鼠李糖乳杆菌及其组合物与应用 | |
US11969447B2 (en) | Use of spray-dried powder derived from lactic acid bacterial strains and herbal extracts for promoting defecation | |
KR101809616B1 (ko) | 항비만효과를 가지는 케피어 유래 프로바이오틱 균주 | |
CN101450083A (zh) | 酪酸梭菌在制备治疗新生儿喂养不耐受组合物中的应用 | |
US20070298018A1 (en) | Novel lactobacillus bulgaricus strain and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240313 Address after: No. 2 Jingyi Road, Huai'an Economic and Technological Development Zone, Huai'an City, Jiangsu Province Patentee after: JINQIAO BIOTECHNOLOGY CO.,LTD. Country or region after: China Address before: No.2, Floor 4, No. 17, International Road, Xinshi District, Tainan City, Taiwan, China, China Patentee before: GLAC BIOTECH Co.,Ltd. Country or region before: Taiwan, China |
|
TR01 | Transfer of patent right |